World Mitochondrial Disease Week
Every year, during the third week of September, the World Mitochondrial Disease Week (WMDW) is being held. This global, important, and rapidly growing event was an initiative from patient organization […]
Delivering mitochondrial health
Every year, during the third week of September, the World Mitochondrial Disease Week (WMDW) is being held. This global, important, and rapidly growing event was an initiative from patient organization […]
Abliva would like to invite interested shareholders and investors to a fun and informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Stockholm […]
Abliva will attend the digital/hybrid event: 21st Annual Biotech in Europe Forum (BEF), on 7 - 8 October 2021.
Italian patient organization Mitocon arranges this year's Mitochondrial Diseases Conference in virtual. Abliva's Chief Medical Officer, Magnus Hansson, will give a flash presentation and join round table discussions at the […]
Abliva will attend Aktiespararna's Kvinnokvällen Malmö, on 19 October 2021.. CEO Ellen Donnelly will be presenting the company at 7:30 p.m. CEST.
Abliva will attend the BioStock Life Science Summit 2021. CEO Ellen Donnelly will be presenting the company on 20 October at 2:00 p.m. CEST.
Abliva will attend the virtual conference Mitochondrial Medicine - Therapeutic Development, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK, on 30 Nov - 2 […]
Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston, MA, USA. The event will be held on 22 - 24 February 2022. CEO Ellen Donnelly will […]
Abliva invites to a conference call and an online presentation on June 1, 2022, at 14:00 CEST. Abliva's CEO Ellen Donnelly, CMO Magnus Hansson and CFO Catharina Johansson will inform […]
Abliva will participate at the United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in Phoenix, Arizona. Abliva's CMO, Magnus Hansson, will participate in a panel discussion on clinical trials together with […]
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about […]
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about […]